After Harvard resigned, students and doctors thought about medical school rankings.

Published Date: 22 Apr 2023

The US News and World Report rankings, once the benchmark by which students evaluated medical schools, have recently begun to lose some of their sway. The value of a school can be evaluated in various ways, according to medical students.

Read Full News

Latest News

'Golden Hour' Rarely Achieved in Rural Trauma Care

Patients with trauma in rural areas travel nearly 190 miles and wait over 7 hours for definitive care, far exceeding the 'golden hour', as per a 10-year Montana study.

Vascular Cognitive Impairment and Dementia

This state of the art review describes the clinical features, pathophysiology, and biomarkers of vascular cognitive impairment and dementia for cardiovascular clinicians.

Impact of Environmental Allergens on Asthma Varies With Age

Older adults may be more vulnerable to asthma, study suggests.

Lymphoma Tx Linked to Mild Photodistributed Skin Reactions

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly photodistributed erythematous patches, a study finds.

EMA Supports First European Therapy for WHIM Syndrome

WHIM syndrome is an ultra-rare hereditary immunodeficiency disease that leads to recurrent severe infections and an increased risk for viral-associated cancer.

Study Backs Longer Compounded Lido Plus Epi Shelf Life

Research supports the safety and efficacy of compounded lidocaine plus epinephrine for up to 24 hours at room temperature and up to 7 days with refrigeration.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

Patients with trauma in rural areas travel nearly 190 miles and wait over 7 hours for definitive care, far exceeding the 'golden hour', as per a 10-year Montana study.

This state of the art review describes the clinical features, pathophysiology, and biomarkers of vascular cognitive impairment and dementia for cardiovascular clinicians.

Older adults may be more vulnerable to asthma, study suggests.

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly photodistributed erythematous patches, a study finds.

WHIM syndrome is an ultra-rare hereditary immunodeficiency disease that leads to recurrent severe infections and an increased risk for viral-associated cancer.

Research supports the safety and efficacy of compounded lidocaine plus epinephrine for up to 24 hours at room temperature and up to 7 days with refrigeration.

News All Time

Earlier Mepolizumab in EGPA May Raise Remission Rate

Initiating mepolizumab within 3 months of EGPA diagnosis is associated with a higher remission rate, earlier glucocorticoid withdrawal, and less damage accrual.

Dupilumab Approved for Allergic Fungal Rhinosinusitis

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

Skin Infections Common in Border Camps

Dermatologic diseases, particularly infections and inflammatory conditions, frequently affect displaced persons at Mexico-US border camps, especially children, according to an analysis.

Heat-Related Emergency Calls Vary by Region and Age

Heat-related emergency medical service activations increased in the US from 2019 to 2024, but overall emergency demand grew faster, with regional and income disparities shaping risk, a study shows.

Fewer Newborns Receive Hepatitis B Vaccination

New data show newborn hepatitis B vaccination rates have dropped, raising concern over rising misinformation.

Dry Eye Disease May Occur Years Before Autoimmune Disease

Dry eye disease affects many people across different autoimmune diseases, ranging in prevalence from about 23% to 81%, and appears about 3 years before diagnosis, a study finds.

US FDA Commissioner Makary Says FDA Supports mRNA Vaccines but US Taxpayers Should Not Bear the Cost

U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to...

NIH Denies Renewal of NIAMS Director’s Contract

Criswell will reportedly stay on as an intramural scientist, continuing to investigate genetic causes of autoimmune diseases.

Omalizumab Appears Superior to Dupilumab in Urticaria

Omalizumab shows superior efficacy to dupilumab in reducing symptoms in patients with chronic spontaneous urticaria.

Brief Program Improves QoL in Patients With Severe Allergies

Small gains in self-efficacy and injectable epinephrine prescription use were measured.

Flu Shot May Boost Survival in Patients With Cancer on ICIs

Patients with advanced cancer receiving influenza vaccination during immunotherapy had longer survival in a Swedish study, with no increase in immune-related toxicities.

Measles Cases in South Carolina Rise by 11 to 973

Measles cases in South Carolina surged to 973 on Friday, state ⁠health data showed, including 11 additional infections since Tuesday.

Going Home: Discharge Tips for CMC Patients

The number of children with medical complexity is growing and an efficient discharge requires a team approach. Here is how to make the transition successful.

Epinephrine Nasal Spray Promising for Urticaria Flares

In a phase 2 trial, patients having an urticaria exacerbation who used the spray report better hive and pruritus scores than the placebo group.

Pediatric Rheum Survey Shows Need to Improve Vaccine Reviews

A consensus statement with more specific guidance on communication practices may help standardize approaches to vaccine-related communication with families, author says.

Novel Combination Therapy: Breakthrough in Brain Metastases?

The combination of stereotactic RT or radiosurgery with immunotherapy or targeted therapy shows manageable toxicity and improved local control and clinical benefit in patients with brain metastases.

Recommended News For You

Healthcare in the Mix in President Biden's Farewell Address

Prostate cancer death risk is higher in late teens and early 20s weight gain.

Why preventive mastectomy isn't offered to everyone at risk

Life quality after childhood cancer is quantifiable thanks to outcome indicators.

The Truth About Apple AirPods

Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.

Could AI plus lasers help catch very early breast cancers?

Recommended Articles For You

What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide  

Personalized Cancer Vaccines and Neoantigen mRNA: A New Era in Oncology 

Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology 

Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Alkem introduces cetuximab under the trade name Cetuxa in India.

2.

When BCG is not effective in treating bladder cancer, Oncolytic Virus exhibits high response rates.

3.

FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

4.

Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US

5.

Antitumor mRNA-based vaccines show potential against gastric cancer metastasis

1.

A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities

2.

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation

3.

New Research on Craniopharyngioma 

4.

Nuclear Medicine's Role in Battling Women's Cancers

5.

Lu-177 Vipivotide in Prostate Cancer: A Breakthrough in Radioligand Therapy

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

2.

Efficient Management of First line ALK-rearranged NSCLC

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

4.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

5.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot